Repligen Corporation (RGEN) Financials
RGEN Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 2.8 billion | 853.2 million |
| 2023-09-30 | 2.5 billion | 525.6 million |
| 2023-06-30 | 2.5 billion | 578.1 million |
| 2023-03-31 | 2.5 billion | 597.7 million |
RGEN Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | 17.9 million | 6.5 million |
| 2023-09-30 | 30.2 million | 6.4 million |
| 2023-06-30 | 25.1 million | 5.5 million |
| 2023-03-31 | 1.7 million | 7.3 million |
RGEN Net Income
No data available :(
RGEN Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 751.3 million | - | 132.2 million |
| 2023-09-30 | 630.8 million | - | 133.9 million |
| 2023-06-30 | 603.7 million | - | 137.3 million |
| 2023-03-31 | 618.0 million | - | 135.6 million |
RGEN Shares Outstanding
RGEN Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 11.1 million | 10.3 million | 57.5 million | - |
| 2023-09-30 | 9.0 million | 10.6 million | 55.5 million | - |
| 2023-06-30 | 9.4 million | 9.7 million | 49.0 million | - |
| 2023-03-31 | 9.4 million | 12.2 million | 57.4 million | - |
RGEN Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 155.7 million | 88.1 million |
| 2023-09-30 | 141.2 million | 104.6 million |
| 2023-06-30 | 159.2 million | 79.3 million |
| 2023-03-31 | 182.7 million | 81.8 million |
RGEN
Price: $166.31
52 week price:
Payout Ratio Range:
Earnings Per Share: 0.74 USD
P/E Ratio: 99.88
Exchange: NMS
Sector: Healthcare
Industry: Medical Instruments & Supplies
Volume: 633600
Ebitda: 2.7 millionMarket Capitalization: 9.8 billion